Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 6/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
| ▸ | RHEB | Q15382 | 3/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7257341 | 0.85 | CYP19A1 (0.45) | CYP19A1IDO1CYP2A6AHRNR4A2 | |
| SCHEMBL30811732 | 0.85 | AHR (0.42) | CYP2A6AHRNR4A2LOXL2HRH4 | |
| SCHEMBL9929376 | 0.85 | AHR (0.42) | CYP2A6AHRNR4A2LOXL2HRH4 | |
| SCHEMBL865591 | 0.84 | CYP19A1 (0.50) | CYP19A1IDO1CYP2A6AHRNR4A2 | |
| SCHEMBL11161860 | 0.81 | CYP19A1 (0.47) | CYP19A1IDO1CYP2A6AHRNR4A2 | |
| SCHEMBL19964554 | 0.81 | LOXL2 (0.62) | CYP19A1IDO1CYP2A6AHRNR4A2 | |
| SCHEMBL31388376 | 0.81 | LOXL2 (0.62) | CYP19A1IDO1CYP2A6AHRNR4A2 | |
| SCHEMBL16440998 | 0.81 | CYP19A1 (0.47) | CYP19A1IDO1CYP2A6AHRNR4A2 | |
| SCHEMBL19013520 | 0.81 | CYP19A1 (0.47) | CYP19A1IDO1CYP2A6AHRNR4A2 | |
| SCHEMBL22529411 | 0.79 | CYP19A1 (0.46) | CYP19A1IDO1CYP2A6AHRNR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111171040-A | Dihydrofuropyran/pyridoindole derivatives and synthesis method thereof | 常州大学 | 2020-05-19 | — | — | CN | claimed |
| CN-106928121-B | High-efficiency preparation method of 3-substituted-benzo five-membered heterocycle-2-carbonyl compound | 暨南大学 | 2020-05-12 | — | — | CN | claimed |
| US-3996241-A | 2-Hydroxymethyl indole compounds and blood sugar lowering compositions | BOEHRINGER MANNHEIM G.M.B.H. (DT) | 1976-12-07 | — | — | US | claimed |
| CN-112823157-B | Spirochroman derivatives | 吉瑞工厂 | 2024-08-09 | — | — | CN | disclosed |
| US-11845742-B2 | Therapeutic compounds and methods to treat infection | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-12-19 | — | — | US | disclosed |
| EP-3820869-B1 | SPIROCHROMANE DERIVATIVES | RICHTER GEDEON NYRT (HU) | 2023-08-30 | — | — | EP | disclosed |
| CN-111225915-B | Imidazopyridine compounds as PAD inhibitors | 朱比兰特埃皮帕德有限公司 | 2023-03-07 | — | — | CN | disclosed |
| EP-3697785-B1 | IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC (US) | 2022-12-28 | — | — | EP | disclosed |
| EP-3697785-B1 | IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC (US) | 2022-12-28 | — | — | EP | disclosed |
| US-11426412-B2 | Imidazo-pyridine compounds as PAD inhibitors | Jubilant Epipad LLC (US) | 2022-08-30 | — | — | US | disclosed |
| US-20210330650-A1 | SPIROCHROMANE DERIVATIVES | RICHTER GEDEON NYRT. (HU) | 2021-10-28 | — | — | US | disclosed |
| US-7459478-B2 | Substituted dihydropyrano indole-3,4-dione derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2008-12-02 | — | — | US | disclosed |
| US-20060270728-A1 | Substituted dihydropyrano indole-3,4-dione derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2006-11-30 | — | — | US | disclosed |
| US-7101903-B2 | Substituted dihydropyrano indole-3,4-dione derivatives as inhibitiors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2006-09-05 | — | — | US | disclosed |
| CN-1726029-A | Substituted dihydropyrano indole-3,4-dione derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) | WYETH CORP (US) | 2006-01-25 | — | — | CN | disclosed |
| EP-1569639-A2 | SUBSTITUTED DIHYDROPYRANO INDOLE-3,4-DIONE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | Wyeth (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20050113436-A1 | 9-(4-Methylbenzyl)-6-[4-(trifluoromethoxy)phenyl]-1,9-dihydropyrano[3,4-b]indole-3,4-dione; treating fibrinolytic disorders, vein thrombosis and coronary heart disease, and pulmonary fibrosis | WYETH (US) | 2005-05-26 | — | — | US | disclosed |
| WO-2004052893-A2 | SUBSTITUTED DIHYDROPYRANO INDOLE-3,4-DIONE DERIVATIVES AND 3-OXOACETIC ACID SUBSTITUTED 2-HYDROXYMETHYLINDOLE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH (US) | 2004-06-24 | — | — | WO | disclosed |
| US-4053624-A | HYPOGLYCEMIC AGENTS | BOEHRINGER MANNHEIM GMBH (DT) | 1977-10-11 | — | — | US | disclosed |
| US-3996241-A | 2-Hydroxymethyl indole compounds and blood sugar lowering compositions | BOEHRINGER MANNHEIM G.M.B.H. (DT) | 1976-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113436-A1 | 9-(4-Methylbenzyl)-6-[4-(trifluoromethoxy)phenyl]-1,9-dihydropyrano[3,4-b]indole-3,4-dione; treating fibrinolytic disorders, vein thrombosis and coronary heart disease, and pulmonary fibrosis | FGB, SERPINE1, MMP1 | CYP19A1 1208/4885IDO1 14/4885CYP2A6 1422/4885 |
| US-20060270728-A1 | Substituted dihydropyrano indole-3,4-dione derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | SERPINE1, TFPI, F2 | CYP19A1 1164/4885IDO1 21/4885CYP2A6 1627/4885 |
| US-20210330650-A1 | SPIROCHROMANE DERIVATIVES | CHRNA7, CHRM3, ADRB3 | CYP19A1 1483/4885IDO1 4166/4885CYP2A6 425/4885 |
| US-11845742-B2 | Therapeutic compounds and methods to treat infection | ABCB11, SLC47A1, SLC47A2 | CYP19A1 4209/4885IDO1 3508/4885CYP2A6 2016/4885 |
| US-11426412-B2 | Imidazo-pyridine compounds as PAD inhibitors | PADI4, PADI1, PADI2 | CYP19A1 976/4885IDO1 921/4885CYP2A6 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.